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Abstract. Background/Aim: We investigated differences in
the clinicopathological and molecular characteristics
between gastric-type mucinous carcinoma (GMC) and usual-
type endocervical adenocarcinoma (UEA). Patients and
Methods: We collected the clinicopathological information
and performed targeted genomic sequencing analysis.
Results: GMCs exhibited significantly deeper invasion depth,
larger horizontal spread, more advanced stage, more
frequent distant metastasis, and more frequent parametrial
and vaginal extension. Disease-free survival time of GMC
patients was significantly shorter than that of UEA patients.
GMCs displayed mutant p53 immunostaining pattern,
whereas UEAs exhibited p16 block positivity. GMCs
harbored mutations in KRAS, TP53, NF1, CDKN2A, STK11,
and ARID1A. One GMC exhibited MDM2 amplification. In
contrast, UEAs harbored mutations in HRAS, PIK3CA, and
BRCA2. Two UEAs were found to have novel TP53
mutations. Conclusion: GMC is associated with more
aggressive behavior than UEA. Distinctive p53 and p16
immunostaining patterns enable differential diagnosis. GMC
and UEA exhibit genetic heterogeneity with potentially
actionable molecular alterations.
Cervical cancer is the fourth most common gynecological
malignancy and the fourth leading cause of cancer-related
death in women worldwide (1, 2), although cervicovaginal
cytology screening decreased the incidence rate of cervical
cancer and its associated mortality rate. Adenocarcinoma of the
uterine cervix is relatively less common than squamous cell
carcinoma and accounts for approximately 10-20% of all
cervical cancers (3, 4). However, despite the declined incidence
of cervical cancer, the proportion of endocervical
adenocarcinoma has increased (4-6). The International
Endocervical Adenocarcinoma Criteria and Classification
(IECC) is a recent system to classify endocervical
adenocarcinoma into human papillomavirus (HPV)-associated
adenocarcinoma (HPVA) and non-HPV-associated
adenocarcinoma (NHPVA) categories based on morphological
features (7). Identification of high-risk HPV, notable mitotic
activity, and numerous apoptotic bodies across the glandular
lumina allowed diagnosing HPVAs. The HPVAs were further
divided into usual type, mucinous type (intestinal type, signet
ring cell type, and not otherwise specified), villoglandular type,
and invasive stratified mucin-producing carcinoma (invasive
stratified mucin-producing intraepithelial lesion), depending on
their cytoplasmic mucin component and nuclear characteristics.
Meanwhile, NHPVAs include gastric-type mucinous carcinoma
(GMC), mesonephric carcinoma, serous carcinoma, clear cell
carcinoma, and endometrioid adenocarcinoma. Among these
carcinomas, GMC, which is the second most common subtype
of endocervical adenocarcinoma, is included in the 2014 World
Health Organization (WHO) Classification of Tumours of
Female Reproductive Organs (1). Although the incidence of
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GMC remains low, it is diagnosed after it progresses into an
advanced disease and presents an aggressive clinical course (7).
In addition to the clinical outcome, two entities exhibit
different pathogenetic mechanisms. HPV infection has been
shown to be not involved in the pathogenesis of GMC, in
which p16 expression is negative or patchy positive (8).
Due to its rarity, clinicopathological and molecular
characteristics of GMC are seldom reported. Despite certain
recent studies that present the morphological features and
targeted sequencing data of GMC (9), the problem of
distinguishing GMC from HPVA remains unresolved. In this
study, we analyzed and compared the clinicopathological and
molecular characteristics of GMC to those of usual-type
endocervical adenocarcinoma (UEA).
Patients and Methods
Case selection. This retrospective study (4-2018-1138) was
reviewed and approved by the Institutional Review Board at the
Severance Hospital (Seoul, Republic of Korea). The study
population comprised 31 consecutive patients who had undergone
hysterectomy and been histologically diagnosed as having invasive
endocervical adenocarcinoma at Severance Hospital (Seoul,
Republic of Korea) from April 2015 to June 2016. All available
hematoxylin and eosin-stained sections were reviewed by two
board-certified pathologists specialized in gynecologic oncology
(H.M.K. and H.-S.K.). All the histological subtypes were
determined according to the WHO Classification (1). Two, two, one,
one, and one patients with clear cell carcinoma, mesonephric
carcinoma, carcinosarcoma, signet-ring cell carcinoma, and serous
carcinoma were excluded. None of the patients was diagnosed as
having endometrioid carcinoma of the uterine cervix. Two patients
who had received preoperative chemotherapy or concurrent
chemoradiation therapy were excluded. Two patients for whom no
specimens were suitable for immunostaining were excluded. Finally,
we extracted eight cases of GMC and 10 cases of UEA.
Clinical and pathological information, including the age of
patients at initial diagnosis, type of surgical treatment, depth of
invasion, largest horizontal spread value, endomyometrial extension,
parametrial extension, vaginal extension, adnexal extension,
involvement of the vaginal and parametrial resection margins,
lymphovascular and perineural invasion, lymph node metastasis,
initial International Federation of Gynecology and Obstetrics
(FIGO) stage, local recurrence, distant metastasis, disease-free
survival (DFS), and overall survival (OS), was obtained from the
electronic medical record system and pathology reports. The
invasion depth and largest horizontal spread were measured directly
on the surgical specimen. Follow-up data after surgery are available
for all patients. Local recurrence and distant metastasis were
revealed based on imaging analyses, including computed
tomography and magnetic resonance imaging. In order to analyze
DFS, the primary endpoint was defined as the time of local
recurrence or distant metastasis – whichever occured first.
Immunohistochemical staining. Immunostaining was performed
using an automatic instrument [Ventana Benchmark XT (Ventana
Medical Systems, Oro Valley, AZ, USA)] (10-18). Antigen retrieval
was performed using the Cell Conditioning Solution (CC1, Ventana
Medical Systems). The 4-μm-thick formalin-fixed paraffin-
embedded (FFPE) sections were incubated with primary antibodies
against p16 (prediluted, clone E6H4; Ventana Medical Systems) and
p53 (1:300, clone DO-7; Novocastra, Leica Biosystems, Newcastle
Upon Tyne, UK). After chromogenic visualization using an
ultraView Universal DAB Detection Kit (Ventana Medical
Systems), sections were counterstained with hematoxylin.
Appropriate positive and negative controls were concurrently
stained to validate the staining method. Endometrial serous
carcinoma and ovarian high-grade serous carcinoma were used as
positive controls for p16 and p53 expression, respectively. Negative
controls were prepared by substituting the non-immune serum for
primary antibodies, which resulted in no detectable staining. The
p53 immunostaining patterns were interpreted as either missense
mutation, nonsense mutation, or wild-type patterns when p53
expression was diffused and strong (>60% of tumor cell nuclei),
completely absent (0%), or focal and weakly positive, respectively
(11, 14, 16, 18, 19). The p16 immunostaining pattern was
interpreted as block-positive when p16 expression was strong and
horizontally continuous, and included nuclear or nuclear-plus-
cytoplasmic staining. All other p16 immunostaining patterns,
including focal or wispy nuclear staining, and blob-like, puddled,
or scattered cytoplasmic staining were interpreted as patchy positive
(13, 14, 19, 20).
HPV genotyping. We performed a polymerase chain reaction (PCR)-
based microarray for HPV genotyping, using a commercially
available HPV 9G DNA chip (BMT HPV 9G DNA Chip, Biometrix
Technology, Chuncheon, Republic of Korea) (20-22). The 9G test
examined the presence of 14 high-risk (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68) and 5 low-risk (6, 11, 34, 40, 42) HPV
types. The PCR mixture consisted of 10 μl of the extracted target
DNA, 10 μl of the primer set (provided by the manufacturer), and
a PCR premix (provided by the manufacturer), which contained
dNTP and Taq DNA polymerase in an amplification buffer.
Amplification was performed using the following steps: pre-
denaturation for 5 min at 94˚C; 40 30-s denaturation cycle at 94˚C;
40 30-s annealing cycle at 45˚C; 40 30-s elongation cycle at 72˚C;
and a final 5-min elongation step at 72˚C. PCR products were
electrophoresed in a 2% agarose gel to confirm successful
amplification. Each hybridization chamber of the 9G was covered
with a mixture of the hybridization solution (35 μl) and PCR
product (15 μl), followed by incubation at 23-26˚C for 30 min. After
washing, array images were scanned and imaged using a fluorescent
scanner (ScanArray GX Microarray Scanner, PerkinElmer Life and
Analytical Sciences, Waltham, MA, USA).
Targeted sequencing. Histological confirmation for the presence of
tumor tissue representing at least 20% of the nucleated cells on the
H&E-stained glass slides was performed by a single board-certified
gynecological pathologist (H.-S.K.), who also marked the densest
tumor area avoiding as much as possible necrotic and hemorrhagic
areas. Ten-micrometer tissue sections were cut from FFPE blocks. The
marked areas were subsequently macrodissected with a scalpel and
brought into 1.5 ml tubes for tissue digestion. Genomic DNA were
extracted using a QIAamp DSP DNA FFPE Tissue Kit (Qiagen,
Valencia, CA, USA). The quantity of the extracted DNA was measured
by the Qubit 2.0 Fluorometer (Life Technologies, Grand Island, NY,
USA). Mutational and copy number analyses were performed using the
TruSight Tumor 170 Kit (Illumina, San Diego, CA, USA) panel (23).
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The gene panels cover 170 genes for mutational analysis and 59 genes
for copy number analysis (Table I). For mutational analysis, fastaq files
were uploaded on the BaseSpace Sequence Hub (Illumina) for variant
interpretation. Only variants in coding regions and promoter regions or
splice variants were retained. In addition, only variants that were
present in <1% of the population according to Exome Aggregation
Consortium (http://exac.broadinstitute.org/) and 1000 Genomes Project
data (https://www.internationalgenome.org/) and present in >5% of
reads with a minimum read depth of 250 were retained. All retained
variants were reviewed by reference websites, including Catalogue of
Somatic Mutations in Cancer (https://cancer.sange0r.ac.uk/cosmic/),
Exome Variant Server (https://evs.gs.washington.edu/EVS/), OncoKB
(https://oncokb.org/), and dbSNP (https://www.ncbi.nlm.nih.gov/snp/),
and only pathogenic variants were selected. In terms of copy number
analysis, genes with more than 2-fold changes relative to the average
level were considered amplified. Genes with less than 0.7-fold changes
relative to the average level were considered to undergo a significant
loss in copy number. We also performed total nucleic acid extraction
to obtain the RNA. RNAs were analyzed for fusion and splice variants
using the ArcherDx FusionPlex Assay and Solid Tumor Assay, which
together cover 55 genes (ArcherDx, Boulder, CO, USA).
Statistical analysis. A Mann-Whitney U-test was performed to
compare differences in continuous variables, such as age, invasion
depth, and horizontal spread, between GMC and UEA. A linear-by-
linear association test was performed to examine whether significant
differences exist in discrete variables between GMC and UEA.
Univariate survival analysis was performed to examine the
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Table I. Gene list for TruSight Tumor 170.
Small nucleotide variant and indels (from DNA)
AKT1                    CCND1                   EP300                     FGF7                   IDH1                       MSH2                       PAX7                         RET
AKT2                    CCND2                   ERBB2                    FGF8                   IDH2                       MSH3                       PDGFRA                  RICTOR
AKT3                    CCNE1                    ERBB3                    FGF9                   INPP4B                   MSH6                       PDGFRB                  ROS1
ALK                      CD79A                    ERBB4                    FGF10                 JAK2                       MTOR                       PIK3CA                    RPS6KB1
APC                      CD79B                    ERCC1                    FGF14                 JAK3                       MUTYH                    PIK3CB                    SLX4
AR                        CDH1                      ERCC2                    FGF23                 KDR                        MYC                         PIK3CD                    SMAD4
ARID1A               CDK12                    ERG                        FGFR1                KIT                          MYCL1                     PIK3CG                    SMARCB1
ATM                     CDK4                      ESR1                       FGFR2                KMT2A                    MYCN                       PIK3R1                     SMO
ATR                      CDK6                      EZH2                      FGFR3                KRAS                       MYD88                     PMS2                        SRC
BAP1                    CDKN2A                 FAM175A                FGFR4                MAP2K1                 NBN                          PPP2R2A                  STK11
BARD1                 CEBPA                    FANCI                     FLT1                    MAP2K2                 NF1                           PTCH1                      TERT
BCL2                    CHEK1                    FANCL                    FLT3                    MCL1                      NOTCH1                  PTEN                        TET2
BCL6                    CHEK2                    FBXW7                   FOXL2                 MDM2                     NOTCH2                  PTPN11                    TMPRSS2
BRAF                   CREBBP                 FGF1                      GEN1                   MDM4                     NOTCH3                  RAD51                      TP53
BRCA1                 CSF1R                     FGF2                      GNA11                 MET                        NPM1                       RAD51B                    TSC1
BRCA2                 CTNNB1                  FGF3                      GNAQ                  MLH1                      NRAS                        RAD51C                   TSC2
BRIP1                  DDR2                      FGF4                      GNAS                   MLLT3                    NRG1                        RAD51D                   VHL
BTK                      DNMT3A                 FGF5                      HNF1A                MPL                        PALB2                       RAD54L                    XRCC2
CARD11               EGFR                      FGF6                      HRAS                   MRE11A                  PAX3                         RB1                           
Copy number variation (from DNA)
AKT2                    CCND3                   ERBB3                    FGF5                   FGF23                     LAMP1                     NRG1                        RICTOR
ALK                      CCN21                    ERCC1                    FGF6                   FGFR1                    MDM2                      PDGFRA                  RPS6KB1
AR                        CDK4                      ERCC2                    FGF7                   FGFR2                    MDM4                      PDGFRB                  TFRC
ATM                     CDK6                      ESR1                       FGF8                   FGFR3                    MET                          PIK3CA                    
BRAF                   CHEK1                    FGF1                      FGF9                   FGFR4                    MYC                         PIK3CB                    
BRCA1                 CHEK2                    FGF2                      FGF10                 JAK2                       MYCL1                     PTEN
BRCA2                 EGFR                      FGF3                      FGF14                 KIT                          MYCN                       RAF1
CCND1                ERBB2                    FGF4                      FGF19                 KRAS                       NRAS                        RET
Fusions and splice variants (from RNA)
ABL1                    BRCA1                    ERG                        FGFR1                JAK2                       MSH2                       NTRK3                      PPARG
AKT3                    FRCA2                    ESR1                       FGFR2                KDR                        MYC                         NTRK3                      RAF1
ALK                      CDK4                      ETS1                       FGFR3                KIF5B                     NOTCH1                  PAX3                         RET
AR                        CSF1R                     ETV1                       FGFR4                KIT                          NOTCH2                  PAX7                         ROS1
AXL                      EGFR                      ETV4                       FLI1                     KMT2A                    NOTCH3                  PDGFRA                  RPS6KB1
BCL2                    EML4                      ETV5                       FLT1                    MET                        NRG1                        PDGFRB                  TMPRSS2
BRAF                   ERBB2                    EWSR1                    FLT3                    MLLT3                    NTRK1                      PIK3CA
prognostic significance of the histological subtype with respect to
DFS and OS. A Kaplan-Meier plot was used to display survival
curves. All statistical analyses were performed using IBM SPSS
Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY,
USA). Statistical significance was defined as p<0.05.
Results
Baseline characteristics. Table II summarizes the baseline
clinicopathological characteristics of patients with GMC or
UEA. The mean ages of eight and 10 patients with GMC and
UEA were 44.2 (range=40-55 years) and 46.8 years
(range=32-63 years), respectively. All patients (8/8; 100.0%)
with GMC underwent radical hysterectomy. Eight (80.0%)
and two (20.0%) of the 10 UEA patients underwent radical
hysterectomy and trachelectomy, respectively. Regarding the
immunostaining results, p16 expression was found to be
block-positive in all UEA cases (10/10; 100.0%), and either
patchy positive (5/8; 62.5%) or negative (3/8; 37.5%) in the
GMC cases. Four (50.0%) cases of GMC exhibited diffuse
and strong nuclear p53 positivity, and the remaining four
(50.0%) cases demonstrated complete loss of p53 expression.
All UEA cases exhibited p53 expression that was patchy and
weakly positive. In HPV genotyping analysis, 10 UEAs
exhibited high-risk HPV, but in GMC, high-risk HPV was
not detected in any of the cases examined. Most (8/10;
80.0%) UEA patients were diagnosed as having FIGO stage
I tumors, whereas all (8/8; 100.0%) GMCs were staged at II
or higher. Three (37.5%) and one (12.5%) patients were
diagnosed with FIGO stage III and IV tumors, respectively.
One patient with FIGO stage IA1 disease received no further
treatment. Eight of the 18 patients whose tumors were FIGO
stage IIB or higher received postoperative concurrent
chemoradiation therapy. The remaining nine patients (FIGO
stage IA2, two; IB1, two; IB2, three; and IIA, two)
underwent postoperative radiation therapy. The mean
postoperative follow-up periods were 29.9 and 44.1 months
in GMC and UEA patients, respectively. Distant metastases
were identified in six (75.0%) GMC patients. The metastatic
organs included the lungs (2/6), ovaries (1/6), liver (1/6),
colon (1/6), and bones (1/6). One patient with Peutz-Jeghers
syndrome (case 7) was diagnosed with GMC. She was
diagnosed with Peutz-Jeghers syndrome nine years ago and
received small bowel resection for ileocolic intussusception
due to multiple hamartomatous polyps of the jejunum. 
Histopathological features. Representative photomicrographs
that depict the histopathological features of GMC and UEA
are shown in Figure 1. GMC consisted of mucin-containing
epithelium, which invades the cervical stroma (Figure 1A).
The tumor cells formed variable-sized, angulated, or cystic
glands, with solid regions and infolded papillae (Figure 1B).
These glands were irregular and dilated (Figure 1C), and
frequently exhibited back-to-back arrangement, cribriform
structure, and solid architecture. Fragmented glands and
individually scattered tumor cells were also noted (Figure
1D). The surrounding stroma demonstrated evident
desmoplasia (Figure 1E), although some foci featured
peritumoral stroma that lacked a desmoplastic response. The
glands, from which the mucin protein is spilled, were lined
by malignant-appearing mucinous epithelium. Inflammatory
infiltrates and fibrosis were associated with one another. The
tumor cells abundantly possessed clear (Figure 1F) or pale
eosinophilic (Figure 1G) cytoplasm with a foamy appearance
and relatively distinct cell borders. The tumor cell nuclei
were enlarged and pleomorphic; furthermore, these nuclei
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Table II. Baseline characteristics of gastric-type mucinous carcinoma
(GMC) and usual-type endocervical adenocarcinoma (UEA).
Characteristic                                                 Number of cases (%)
                                                               GMC (n=8)           UEA (n=10)
Age (years)
  Mean±Standard deviation                     44.2±4.7                46.8±11.3
  Range                                                       40-55                      32-63
Invasion depth (mm)
  Mean±Standard deviation                     17.3±3.6                  6.8±4.0
  Range                                                       14-23                       2-14
Horizontal spread (mm)
  Mean±Standard deviation                    35.0±10.4               21.6±14.9
  Range                                                       23-54                       4-50
Type of surgical treatment
  Radical hysterectomy                           8 (100.0)                 8 (80.0)
  Radical trachelectomy                            0 (0.0)                   2 (20.0)
p16 expression
  Block positive                                         0 (0.0)                 10 (100.0)
  Patchy positive                                       5 (62.5)                   0 (0.0)
  Negative                                                 3 (37.5)                   0 (0.0)
p53 expression
  Diffuse, strong positive                         4 (50.0)                   0 (0.0)
  Complete loss                                        4 (50.0)                   0 (0.0)
  Patchy positive                                        0 (0.0)                 10 (100.0)
Human papillomavirus status
  High-risk detected                                  0 (0.0)                 10 (100.0)
  Not detected                                           7 (87.5)                   0 (0.0)
  Not applicable                                        1 (12.5)                   0 (0.0)
Initial stage
  I                                                                0 (0.0)                   8 (80.0)
  II                                                             4 (50.0)                   0 (0.0)
  III                                                            3 (37.5)                  2 (20.0)
  IV                                                            1 (12.5)                   0 (0.0)
Local recurrence
  Present                                                    1 (12.5)                  2 (20.0)
  Absent                                                    7 (87.5)                  8 (80.0)
Distant metastasis
  Present                                                    6 (75.0)                  1 (10.0)
  Absent                                                    2 (25.0)                  9 (90.0)
Follow-up period (month)
  Mean±Standard deviation                        29.9                        44.1
  Range                                                       12-41                      30-51
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Figure 1. Histopathological features of gastric-type mucinous carcinoma (GMC; A to G) and usual-type endocervical adenocarcinoma (UEA; H to
N). A: GMC consists of variable-sized, irregular-shaped glands that are lined by mucin-containing epithelium and infiltrate the cervical stroma. B:
The tumor cells form angulated or complicated glands that anastomose each other. C: These glands invade haphazardly the deep cervical stroma
and are associated with stromal desmoplasia. D: The fragmented glands and individually scattered tumor cells are admixed with extensive
lymphoplasmacytic and eosinophilic stromal infiltrates. E: The surrounding stroma demonstrates the fibromyxoid desmoplastic reaction. F: The
tumor cells possess abundant clear cytoplasm with a foamy appearance and relatively distinct cell borders. G: The tumor cell nuclei are enlarged
and pleomorphic and exhibit coarse chromatin, variable-sized nucleoli, and membrane irregularity. H: UEA displays a complex glandular
architecture, consisting mainly of cribriform glands and some dilated glandular lumina. I: The tumor cells demonstrate characteristic
pseudostratified columnar epithelium with elongated, hyperchromatic nuclei. J: The tumor cell nuclei possess conspicuous nucleoli. Mitotic figures
were frequently identified, especially in the apical zone of the amphophilic to eosinophilic cytoplasm. K: Apoptotic bodies and karyorrhectic debris
are readily visible within the epithelium and glandular spaces. L: In a single case of UEA, the microcystic, elongated, and fragmented (MELF)
patterns of invasion are noted. At the invasive tumor front (*), the tumor cells or glands were obscured by striking stromal desmoplasia and
myxoinflammatory responses. Thus, they are not apparent at low-power magnification. M: The tumor cells demonstrate eosinophilic or vacuolated
cytoplasm and are surrounded by a fibromyxoid or edematous stroma that is associated with inflammatory cells. N: In some foci, the tumor cell
clusters exhibit epithelioid morphology, resembling histiocytes that are aggregated within lymphatic spaces (black arrows). A to N, hematoxylin
and eosin staining. Original magnification, A to C, ×40; D and E, ×100; F and G, ×200; H, ×40; I, ×200; J and K, ×400; L, ×40; M and N ×200.
exhibited coarse chromatin, variable-sized nucleoli, and
membrane irregularity. Mitotic and apoptotic activities were
low, and atypical mitotic figures were not identified. In cases
with parametrial extension, the neoplastic glands infiltrated
through the entire cervical stroma into the parametrial
fibroadipose tissue. The glands and associated stromal
desmoplasia were identified between thick-walled blood
vessels. In three of the six metastatic tumors, several foci of
signet ring cell differentiation (2/6) and dedifferentiation
with sarcomatoid morphology (1/6) were observed.
UEA displayed complex architectural patterns (Figure 1H),
which consisted of round-to-oval shape, mucin-poor glands,
microcysts, and cribriform structures. The dilated glandular
lumina contained necrotic debris. The tumor cells exhibited a
characteristic pseudostratified columnar epithelium with
enlarged, elongated, and hyperchromatic nuclei (Figure 1I).
The tumor nuclei possessed conspicuous nucleoli. Mitotic
figures were frequently identified, especially in the apical zone
of the amphophilic-to-eosinophilic cytoplasm (Figure 1J).
Apoptotic bodies and karyorrhectic debris were readily visible
within the epithelium and glandular spaces (Figure 1K).
Although most areas exhibited relative mucin depletion and
pseudostratified nuclei, mucin pools and a single layer of the
columnar epithelium with appreciable intracytoplasmic mucin
were noted.
In a single case of UEA, microcystic, elongated, and
fragmented (MELF) patterns of invasion were noted. At the
invasive tumor front, the tumor glands displayed a microcystic
and elongated appearance and were lined by flattened
epithelium. Since the tumor cells or glands were obscured by
striking stromal desmoplasia and the myxoinflammatory
response, they were not apparent at low-power magnification
(Figure 1L). The tumor cells exhibited eosinophilic or
vacuolated cytoplasm and were surrounded by a fibromyxoid
or edematous stroma that was associated with inflammatory
cells (Figure 1M). In some foci, the tumor cell clusters
exhibited epithelioid morphology, resembling histiocytes that
were aggregated within the lymphatic spaces (Figure 1N).
In case 7, lobular endocervical glandular hyperplasia
(LEGH) was associated with GMC. Distinctly lobular
architecture was noted with proliferated small round glands
that surround a central cystically dilated duct (Figure 2A).
The lesion was confined to the inner half of the cervical wall
and located within the upper endocervix (Figure 2B). Each
gland was lined by mucin-containing columnar cells (Figure
2C), and possesses basally located, uniform, and small nuclei
(Figure 2D). No nuclear atypia was found. The intervening
stroma was unremarkable (Figure 2E), without desmoplasia
or significant inflammation.
Representative photomicrographs that depict immuno-
reactivities for p53 and p16 in GMC and UEA are shown in
Figure 3. In GMCs (Figure 3A), p16 expression was patchy
positive (5/8) or negative (3/8; Figure 3B). All GMCs
expressed a mutant p53 expression pattern. Three of the
eight GMCs displayed completely negative for p53
immunostaining (nonsense of frameshift mutation pattern;
Figure 3C), and the remaining four cases showed uniform
and strong p53 expression in nearly all the tumor cell nuclei
(missense mutation pattern; Figure 3D). In contrast, all
UEAs (Figure 3E) demonstrated diffuse and strong nuclear
immunoreactivity for p16 (block p16 positivity; Figure 3F)
and patchy and weak-to-moderate nuclear immunoreactivity
for p53 (wild-type p53 expression pattern; Figure 3G).
Clinicopathological differences. Table III summarizes the
clinicopathological differences between GMC and UEA.
GMC exhibited significantly deeper invasion depth (mean:
17.3 mm versus 6.8 mm; p<0.001), greater horizontal spread
(mean: 35.0 mm versus 21.6 mm; p=0.039), more advanced
FIGO staging (p=0.001), and more frequent distant metastasis
(p=0.013) than UEA. Additionally, parametrial extension
(p=0.015), parametrial resection margin involvement
(p=0.023), vaginal extension (p=0.043), and vaginal resection
margin involvement (p=0.023) were more frequently observed
in GMC than in UEA. All of the UEA cases exhibited negative
resection margins in the vagina or parametrium, whereas half
of the GMCs involved either vaginal or parametrial resection
margins. No statistically significant differences were found in
lymphovascular invasion, perineural invasion, adnexal
extension, peritoneal metastases, and lymph node metastasis
between GMC and UEA.
Differences in patient outcome. Kaplan-Meier plots for DFS
and OS are shown in Figure 4. During the follow-up period,
one (12.5%) and six (75.0%) GMC patients developed
recurrence and metastasis, respectively. The DFS rate for
GMC patients was significantly lower than that for UEA
patients (p=0.032; Figure 4A). The median DFS time for
patients with GMC was 19 months, compared to more than
four years for UEA patients. Patients with UEA had stable
DFS rates of 90% between one and two years after surgery
and 80.0% after two and a half years. In contrast, GMC
patients displayed a steady decline in the DFS rate during the
first two years after surgery. DFS rates for GMC patients were
62.5% for one year and 25.0% for two years. In addition, the
OS time for GMC patients was shorter than that of patients
with UEA, although the difference in the OS rate between the
two groups was not statistically significant (p=0.076; Figure
4B). The OS rate for UEA patients was over 90.0% during the
observation period (51 months), whereas the OS rate for GMC
patients at the last follow-up was only 36.5%.
Targeted sequencing results. Table IV and Figure 5 summarize
the pathogenic mutations that were detected in GMC and UEA
tissue samples. All except one patient harbored at least one
pathogenic mutation. Two GMCs (case 1 and 2) that harbored
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Figure 3. Immunostaining results of gastric-type mucinous carcinoma (GMC; A to D) and usual-type endocervical adenocarcinoma (UEA; E to G).
(black arrows). A: GMC. B: The GMC cells do not express p16, indicating that this tumor is independent of the human papillomavirus (HPV)
infection. Instead, the spindle- or stellate-shaped stromal cells exhibit strong nuclear and cytoplasmic immunoreactivity for p16. C and D: p53
immunostaining reveals that the GMC cells display complete loss (C) or diffuse and strong expression (D), indicating the presence of the tumor
protein 53 (TP53) mutation. E: UEA. F: The UEA cells demonstrate diffuse and strong nuclear p16 expression (block p16 positivity), indicating
that UEA is associated with high-risk HPV infection. G: In contrast to p16 expression, p53 expression is weak and patchy in scattered tumor cells,
indicating wild-type TP53. A and E, hematoxylin and eosin staining; B to D, F, and G, polymer method. Original magnification, A to D, ×100; E,
×100; F and G, ×200.
Figure 2. Histopathological features of lobular endocervical glandular hyperplasia. A: A distinctly lobular architecture consists of small round
glands and cystically dilated ducts. B: The lesion is confined to the inner half of the cervical wall and. C: Each gland is lined by mucin-containing
columnar epithelium. D: The epithelial cells possess basally located, uniform nuclei. Each cell does not exhibit any nuclear pleomorphism. E: The
intervening stroma displays no inflammation or desmoplasia. A to E, hematoxylin and eosin staining. Original magnification, A, ×12.5; B, ×40; C,
×100; D, ×200; E, ×400.
missense TP53 (tumor protein 53) mutations [c.724T>A
(p.Cys242Ser) and c.818G>A (pArg273His)], which were
compatible with diffuse and strong nuclear p53
immunoreactivity (missense mutation pattern of p53
expression). Each of the two cases exhibited an additional
mutation, including the missense KRAS (Kirsten rat sarcoma
viral oncogene homolog) mutation [c.35G>A (p.Gly12Asp)]
and frameshift deletion of the NF1 (neurofibromin 1) gene
[c.3037delA (p.Thr1013Argfs)]. The latter mutation was also
detected in another case of GMC (case 3). Three cases of GMC
harbored nonsense (case 4) and missense (case 5) mutations and
frameshift insertion (case 7) of the CDKN2A (cyclin-dependent
kinase inhibitor 2A) gene [c.172C>T (p.Arg58Ter), c.224C>T
(p.Pro75Leu), and c.213_214insT (p.Arg71fs), respectively]. In
addition, a patient with Peutz-Jeghers syndrome (case 7) was
identified to foster the STK11 (serine/threonine kinase 11)
mutation [c.470T>G (p.Phe157Cys)], along with the missense
KRAS mutation [c.176C>G (p.Ala59Gly)] and nonsense
ARID1A (AT-rich interaction domain 1A) mutation [c.802C>T
(p.Gln268Ter)]. In a single case of GMC (case 6), MDM2
(mouse double minute 2 homolog) amplification was detected.
Half (5/10) of the UEA cases harbored at least one
pathogenic mutation. The HRAS (Harvey rat sarcoma viral
oncogene homolog) missense mutation [c.34G>T
(p.Gly12Cys)] was detected in one case (case 1). This case
also exhibited the TP53 splice site mutation (c.376-2A>T),
which was identified in another case (case 2). Two cases
(case 3 and 4) harbored the PIK3CA (phosphatidylinositol-
4,5-bisphosphate 3-kinase catalytic subunit alpha) missense
mutation [c.1633G>A (p.Glu545Lys)]. The BRCA2 (breast
cancer 2, early onset) nonsense mutations [c.8951C>A
(p.Ser2984Ter) and c.1850C>A (p.Ser617Ter)] were
identified in two cases, one of which harbored the PIK3CA
mutation (case 4), and the other (case 5) of which harbored
the BRCA2 mutation only.
Discussion
We observed that GMC, compared to UEA, was significantly
associated with larger horizontal spread, deeper invasion
depth, parametrial extension, vaginal extension, more
advanced staging, and distant metastasis. These findings
clearly confirm the notion that GMC is diagnosed at
advanced stages and displays more aggressive behavior than
UEA (7). GMC frequently metastasizes to the extrapelvic
organs and exhibits worse prognosis (24). Our results are
consistent with those of a recent study by Nishio et al. (25)
with the largest GMC cohort, which ultimately demonstrated
that GMC is more significantly associated with bulky mass,
deep stromal invasion, and parametrial invasion than UEA.
Our observations that all GMC cases classified as FIGO
stage II-IV, but the majority (80.0%) of the UEA patients had
FIGO stage I tumors is in accordance with those of
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Table III. Clinicopathological differences between gastric-type
mucinous carcinoma (GMC) and usual-type endocervical
adenocarcinoma (UEA).
Characteristic                                     Number of cases (%)        p-Value
                                                             GMC             UEA                 
Age                                                    44.2±4.7      46.8±11.3        0.542
Invasion depth (mm)                         17.3±3.6        6.8±4.0        <0.001*
Horizontal spread (mm)                   35.0±10.4     21.6±14.9        0.039*
Parametrial extension
  Present                                             7 (87.6)        2 (20.0)          0.015*
  Absent                                              1 (12.5)        8 (80.0)            
Parametrial resection 
margin involvement
  Present                                             4 (50.0)         0 (0.0)           0.023*
  Absent                                              4 (50.0)      10 (100.0)          
Endomyometrial
extension
  Present                                             4 (50.0)        4 (40.0)          1.000
  Absent                                              4 (50.0)        4 (40.0)            
  Not applicable                                  0 (0.0)         2 (20.0)            
Vaginal extension
  Present                                             5 (62.5)        1 (10.0)          0.043*
  Absent                                              3 (37.5)        9 (90.0)            
Vaginal resection
margin involvement
  Present                                             4 (50.0)         0 (0.0)           0.023*
  Absent                                              4 (50.0)      10 (100.0)          
Lymphovascular
invasion
  Present                                             3 (37.5)        4 (40.0)          1.000
  Absent                                              5 (62.5)        6 (60.0)            
Perineural invasion
  Present                                             3 (37.5)        1 (10.0)          0.275
  Absent                                              5 (62.5)        9 (90.0)            
Adnexal extension
  Present                                             1 (12.5)        2 (20.0)          1.000
  Absent                                              7 (87.5)        8 (80.0)            
Pelvic peritoneal
metastasis
  Present                                             1 (12.5)         0 (0.0)           0.444
  Absent                                              7 (87.5)      10 (100.0)          
Extrapelvic peritoneal
metastasis
  Present                                             1 (12.5)         0 (0.0)           0.444
  Absent                                              7 (87.5)      10 (100.0)          
Lymph node
metastasis
  Present                                             4 (50.0)        2 (20.0)          0.321
  Absent                                              4 (50.0)        8 (80.0)            
Initial stage
  I                                                         0 (0.0)         8 (80.0)          0.001*
  II-IV                                                8 (100.0)       2 (20.0)            
Local recurrence
  Present                                             1 (12.5)        2 (20.0)          1.000
  Absent                                              7 (87.5)        8 (80.0)            
Distant metastasis
  Present                                             6 (75.0)        1 (10.0)          0.013*
  Absent                                              2 (25.0)        9 (90.0)            
*Statistically significant.
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Figure 5. Targeted sequencing results, immunophenotype, and human papillomavirus (HPV) status of gastric-type mucinous carcinoma (GMC) and
usual-type endocervical adenocarcinoma (UEA).
Figure 4. Kaplan-Meier plots for disease-free survival (DFS) (A) and overall survival (OS) (B) of patients with gastric-type mucinous carcinoma
(GMS) or usual-type endocervical adenocarcinoma (UEA). The survival rates are indicated in red for GMC and in blue for UEA. A: DFS rate for
GMC patients is significantly lower than that for UEA. B: OS time for GMC patients is also shorter than that of patients with UEA, although the
difference in the OS rate between the two groups was not statistically significant.
Karamurzin et al. (24), which showed that GMC presents at
more advanced stages than UEA. Nishio et al. (25) reported
that lymphovascular invasion, ovarian metastasis, pelvic
lymph node metastasis, and recurrence, all of which are
conventional pathological features that predict worse
prognosis, were more frequently observed in GMC compared
to in UEA. However, a significant difference was not
observed in the frequency of the lymphovascular invasion,
adnexal extension, lymph node metastasis, and local
recurrence between GMC and UEA. This discrepancy may
be attributed to the small number of cases in this study.
Nevertheless, we noted that GMC patients developed more
frequently metastases to distant organs, including the lungs,
liver, ovaries, and colon, than those with UEA. In addition,
we found that the surgical resection margin involvement in
the vagina and parametrium – which is an important risk
factor for postoperative recurrence (26, 27) – was more
frequent in GMC than in UEA, thus suggesting that
additional treatments should be considered to improve local
control, such as radiation boosting, in GMC patients.
Despite a small number of cases, we demonstrated that the
DFS rate for GMC patients was significantly lower than that
for UEA patients. The median DFS time for GMC was 19
months, compared to more than four years for UEA. GMC
patients displayed a steady decline in the DFS rate up to
25.0% during the first two years after surgery, whereas UEA
patients exhibited stable DFS rates of 80.0% or higher for two
and a half years after surgery. The OS time for GMC patients
was also shorter than that of patients with UEA, although the
difference between the two groups was not statistically
significant. Our results are consistent with those of previous
studies. Kojima et al. (28) found that GMC patients (30%) had
a significantly lowered five-year DFS rate compared to the
non-gastric type (77%), and gastric-type morphology exhibited
a significant risk for disease recurrence with a hazard ratio of
4.5. Nishio et al. (25) documented that both DFS and OS were
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Table IV. Pathogenic mutations in gastric-type mucinous carcinoma (GMC) and usual-type endocervical adenocarcinoma (UEA).
Case No                               Gene                                         Mutation type                                  Sequence change                             Predicted effect
GMC
1                                           KRAS                                             Missense                                             c.35G>A                                      p.Gly12Asp
                                             TP53                                             Missense                                            c.724T>A                                     p.Cys242Ser
2                                           TP53                                             Missense                                            c.818G>A                                     pArg273His
                                              NF1                                             Frameshift                                          c.3037delA                                 p.Thr1013Argfs
3                                            NF1                                             Frameshift                                          c.3037delA                                 p.Thr1013Argfs
4                                        CDKN2A                                          Nonsense                                            c.172C>T                                      p.Arg58Ter
5                                        CDKN2A                                          Missense                                            c.224C>T                                      p.Pro75Leu
6                                          MDM2                                Copy number variation                              Amplification                                Overexpression
7                                           KRAS                                             Missense                                            c.176C>G                                      p.Ala59Gly
                                            STK11                                            Missense                                            c.470T>G                                     p.Phe157Cys
                                         CDKN2A                                         Frameshift                                       c.213_214insT                                   p.Arg71fs
                                          ARID1A                                          Nonsense                                            c.802C>T                                     p.Gln268Ter
8                                     Not detected                                                                                                                                                                   
UEA
1                                           HRAS                                             Missense                                             c.34G>T                                       p.Gly12Cys
                                             TP53                                  Splice acceptor variant                               c.376-2A>T
2                                           TP53                                  Splice acceptor variant                               c.376-2A>T                                              
3                                         PIK3CA                                           Missense                                           c.1633G>A                                    p.Glu545Lys
4                                         PIK3CA                                           Missense                                           c.1633G>A                                    p.Glu545Lys
                                           BRCA2                                           Nonsense                                           c.8951C>A                                   p.Ser2984Ter
5                                         BRCA2                                           Nonsense                                           c.1850C>A                                    p.Ser617Ter
6                                     Not detected                                                                                                                                                                   
7                                     Not detected                                                                                                                                                                   
8                                     Not detected                                                                                                                                                                   
9                                     Not detected                                                                                                                                                                   
10                                   Not detected                                                                                                                                                                   
KRAS: Kirsten rat sarcoma viral oncogene homolog, TP53: tumor protein 5, NF1: neurofibromin 1, CDKN2A: cyclin-dependent kinase inhibitor 2A,
MDM2: mouse double minute 2 homolog, STK11: serine/threonine kinase 11, ARID1A: AT-rich interaction domain 1A, HRAS: Harvey rat sarcoma
viral oncogene homolog, PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, BRCA2: breast cancer 2, early onset.
worse in patients with GMC than in those with UEA.
Karamurzin et al. (24) also reported that GMC exhibited
significantly worse disease-specific survival than UEA.
Similarly, Park et al. (29) showed that GMC had a
significantly shorter interval between surgery and disease
recurrence (time to recurrence) compared to UEA. Overall,
GMC exhibits aggressive behavior with significantly reduced
survival compared to UEA, and GMC is thus considered a
distinct entity from UEA.
In this study, we identified mutually exclusive expression
of p16 and p53 in UEA and GMC. In all 10 cases of UEA
with p16 block-positivity, p53 immunoreactivity was focal
and weak, indicating wild-type TP53. In contrast, all eight
cases of GMC displayed mutant p53 immunostaining
patterns (either diffuse and strongly positive or complete
absence) and non-block-type (patchy) p16 expression. These
results are in accordance with the HPV-negative status of
GMC and the findings of the recent study by Garg et al. (9),
which show that all 14 GMCs demonstrated non-block p16
immunoreactivity – consisting of 12 cases with negative
expression, one case with focal staining, and one case with
patchy expression. Our findings suggest that immunostaining
for p16 and p53 allows distinguishing between UEA and GMC.
However, in contrast to our results, diffuse and strong nuclear
p16 expression has been reported in a rare subset of GMC
despite negative molecular testing for HPV (30-32). Moreover,
not all GMCs display mutant p53 immunostaining patterns.
Garg et al. (9) reported that aberrant p53 expression was
observed in nine of 14 GMCs. Similarly, in a previous study by
Carleton et al. (30), which featured immunohistochemical
analyses on cervical and vaginal GMCs, p53 exhibited wild-
type and mutant immunostaining patterns in 27 (58.7%) and 19
(41.3%) of the 46 total cases, respectively. Further, two of four
GMCs that were reported to exhibit p16 block positivity were
negative for HPV. These findings indicate that p16
immunoreactivity in endocervical adenocarcinomas are not
necessarily indicative of high-risk HPV-associated tumors, and
that p53 expression patterns do not serve as an absolute
diagnostic marker to diagnose GMC.
The molecular characteristics of GMC have recently been
analyzed using the next-generation sequencing (NGS)
technique (33). In the 14 GMCs that were examined, variants
were detected most frequently in the TP53, MSH6, CDKN2A,
CDKN2B, POLE, SLX4, ARID1A, STK11, BRCA2, and MSH2
genes. Mutations in genes that are associated with one or many
of the following pathways were also identified: homologous
recombination deficiency, mismatch repair, cell cycle, Fanconi
anemia pathway, Notch signaling, and phosphotidylinositol 3-
kinase/Akt signaling. In accordance with these data, we
observed GMCs with mutations in the TP53, CDKN2A,
ARID1A, and STK11 genes. Garg et al. (9) found that GMC
resembles endometrial cancer more closely than UEA, in terms
of molecular features, since it harbors mutations in the KRAS,
MSH2, MSH6, and POLE genes—mutations that are found in
endometrial cancer, but not in UEA.
We noted a MDM2 amplification in a single case of GMC.
This is consistent with the study by Garg et al. (9), which
identified the same copy number abnormality in two GMC
cases. Interestingly, although these two cases were reported to
exhibit wild-type p53 immunostaining patterns, our cases
suggest that MDM2 amplification demonstrated diffuse and
strong p53 expression (missense mutation pattern) without
TP53 mutation. MDM2 is a negative regulatory factor for p53.
MDM2 ubiquitinate degrades p53 protein through close-loop
negative feedback regulation of MDM2-p53, thereby reducing
p53 protein levels (34). Several studies confirm that MDM2
amplification down-regulates p53 expression, and that
inhibition of MDM2 expression induces p53 up-regulation (34,
35). Based on the well-known functions of MDM2, our
observation of concurrent MDM2 amplification and missense
mutation pattern of p53 expression is an uncommon
observation. Nevertheless, complex interactions of intracellular
signaling pathways that activate p53-related pathways and
stabilize the p53 protein are apparent, and our results suggest
the possibility of MDM2-independent regulatory mechanisms
that up-regulate p53 protein expression.
We observed splice-site mutations of the TP53 gene in
two cases of UEA. No study has found splice-site mutations
of TP53 in UEA. The TP53 splice-site mutation (c.376-
2A>T) that we observed had been observed in ovarian cancer
and Li-Fraumeni syndrome (36). Although the splice-site
mutations of TP53 are very scarce in UEA and their effects
have not been well characterized, the possibility that the
novel splice-site mutation in this study is involved in the
pathogenesis of UEA cannot be excluded. In addition, tubo-
ovarian high-grade carcinoma with TP53 splice-site
mutations (c.920-6_922delTCCTAGCAC and c.920-2delA)
was found to exhibit wild-type expression patterns in the p53
immunostaining results (18). This study showed patchy and
weak p53 expression in two cases of UEA with TP53 splice-
site mutations. Although it is known that the p53
immunostaining pattern and TP53 mutational status are
correlated in more than 95% of tubo-ovarian high-grade
carcinoma, false-negative staining can occur in a small
subset of cases. Since no previous studies have compared
p53 expression status and TP53 mutational status in UEA,
their correlation cannot be determined. However, we suspect
that the discordance between the novel splice-site mutation
of the TP53 gene and wild-type p53 immunostaining pattern
that was observed in this study is rare.
Peutz-Jeghers syndrome is an autosomal-dominant
disorder that carries a mutation in the STK11 gene, which is
a tumor suppressor gene that is located in chromosome
19p13.3 (9). Approximately 14% of GMCs were reportedly
associated with Peutz-Jeghers syndrome (37). In this study,
we presented a case of GMC that was associated with the
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STK11 mutation and LEGH in a 39-year-old patient with
Peutz-Jeghers syndrome who received segmental resection
of the small bowel for multiple gastric and jejunal
hamartomatous polyps and ileocolic intussusception. LEGH
is usually detected incidentally in a hysterectomy or cervical
conization specimen. Patients presented watery or mucoid
vaginal discharge, which suggests minimal deviation
adenocarcinoma (MDA) of the cervix. In this situation,
imaging findings may also raise concerns for MDA or GMC,
since LEGH appears as a multicystic lesion that occupies the
cervix either partially or entirely. Histologically,
distinguishing LEGH from MDA is difficult. Architectural
pattern at low-power magnification is critical and best
observed in a resected specimen. LEGH exhibits the orderly
lobular arrangement of mucinous glands that are usually
confined to the inner half of the cervical wall, whereas MDA
displays a haphazard glandular arrangement of various sizes
and shapes that widely infiltrate the stroma, usually with a
focal desmoplastic response and nuclear atypia (24, 25).
Lymphovascular or perineural invasion and parametrial
extension, if present, assist in establishing a diagnosis of
malignancy (36). In addition, we identified the STK11
mutation [c.470T>G (p.Phe157Cys)] and KRAS mutation
[c.176C>G (p.Ala59Gly)] from the GMC tissue. This finding
of the co-existence of the KRAS mutation [c.187G>A
(p.Glu63Lys)] and STK11 truncation variant [c.396C>A
(p.Cys132Ter)] in one case of GMC is consistent with a
previous study by Garg et al. (9). Additionally, Matsubara et
al. (38) found mutations in one of the following genes in
LEGH: the GNAS, KRAS, and STK11 genes. Further, they
observed that these mutations are mutually exclusive. These
results suggest that LEGH is associated with the
transformation and progression process to GMC. In line with
these data, Shibata et al. (39) reported that hepatobiliary
mucinous cystic neoplasms with abundant mucinous
epithelium harbored KRAS mutations more frequently and
show higher risk of malignant progression compared to those
with poor intracytoplasmic mucin. Although identifying
mutations in the LEGH tissue has been performed, genetic
aberrations that initiate or accelerate progression from LEGH
to GMC remain to be explored. 
We also presented a scarce case of UEA with the MELF
pattern of stromal invasion. The MELF pattern of invasion
represents a very distinctive morphological pattern of
myometrial invasion of endometrial endometrioid carcinomas
(40). Even though a recent study has described MELF
invasion pattern in endocervical adenocarcinoma (41), little
information is available on the clinicopathological significance
of the MELF invasion pattern in UEA. Since this pattern of
invasion is not familiar to pathologists, for accurate diagnosis,
they must know that the MELF invasion pattern can be
observed in UEA. Many previous studies reported that the
MELF invasion pattern is significantly related to more
frequent lymphovascular invasion and isolated tumor lymph
node metastasis, as well as poor prognosis of patients with
endometrial carcinoma (42, 43). Espinosa et al. (44) observed
that MELF-positive endometrioid carcinoma cases had more
frequent lymph node metastases than those without MELF.
Zinovkin et al. (45) reported that the survival rate of patients
whose tumors show MELF invasion pattern was significantly
lower when compared with MELF-negative patients. Sanci et
al. (46) also documented that the presence of MELF invasion
pattern was a substantial risk factor for detecting lymph node
involvement in patients with grade 1-2 endometrial
endometrioid carcinoma, and its effect on OS was significant.
These data suggest that the MELF invasion pattern can be a
potential risk factor for lymph node metastasis, and for
appropriate management, pathologists need to not overlook the
MELF invasion pattern when diagnosing UEA. However,
prognostic implications of MELF invasion pattern have not
been completely established. In studies involving low-grade
endometrial endometrioid carcinoma (39), even though the
MELF invasion pattern was significantly associated with
larger tumor sizes, myometrial invasion greater than 50%,
advanced stages, lymphovascular invasion, and lymph node
metastasis, patients who exhibited the MELF invasion pattern
did not exhibit worse prognosis compared to those without the
MELF invasion pattern. A recent study that analyzed the
prognostic value of the MELF invasion pattern in a large
cohort of patients with endocervical adenocarcinoma (41)
demonstrated lower OS rates and shorter median survival in
MELF-positive patients compared to MELF-negative patients.
Regarding the insignificant adverse impact on patient
outcomes, some previous studies on endometrial endometrioid
carcinoma documented that the MELF component displayed
very low proliferative activity or lack or Ki-67 labeling index
and p21 expression (40, 47) compared to the areas of
conventional invasion, indicating growth arrest or senescence
of the MELF-type tumor element. The difference in the
expression of proliferative and senescence markers may
explain why the presence of MELF invasion pattern did not
show any prognostic significance despite its association with
frequent lymphovascular invasion and lymph node metastasis.
Even though MELF was not independently associated with
survival, previous data support the possibility that the
pathological characteristics of MELF-positive tumors and
MELF-negative tumors are different to each other. Therefore,
although the prognostic value of the MELF invasion pattern
in endocervical adenocarcinoma has not been fully
established, pathologists should carefully determine the MELF
invasion pattern in UEA (41). In addition, further studies are
necessary to confirm the prognostic significance of this
unusual pattern of invasion in UEA.
In conclusion, we demonstrated significant differences in
clinicopathological and molecular characteristics between
GMC and UEA. In comparison to UEA, GMC exhibited
CANCER GENOMICS & PROTEOMICS 17: 627-641 (2020)
638
significantly deeper invasion depth, larger horizontal spread,
and more advanced stage. In addition, the parametrial and
vaginal extension with resection margin involvement and
distant metastasis were more frequently observed in patients
with GMC than in those with UEA. The disease-free survival
time of GMC patients was significantly shorter than that of
UEA patients. These findings confirm that GMC is a more
aggressive subtype of endocervical adenocarcinoma than
UEA, and that patient outcomes of GMC are worse than
those of UEA. Mutually exclusive immunostaining patterns
for p16 and p53 were found in UEA and GMC. All GMCs
displayed the mutant p53 immunostaining pattern, whereas
all UEAs exhibited wild-type p53 expression. In contrast, p16
expression was block-positive in all UEAs, but negative or
patchy positive in GMCs, which suggests that the distinctive
expression of p53 and p16 allows differentiating between
UEA and GMC diagnoses. In addition, GMCs harbored
pathogenic mutations in KRAS, TP53, NF1, STK11,
CDKN2A, and ARID1A. Further, GMC also harbored MDM2
amplification. In contrast, UEAs exhibited different molecular
profiles, in which mutations in HRAS, PIK3CA, and BRCA2
were harbored, which suggests that GMC and UEA exhibit
genetic heterogeneity with potentially actionable molecular
alterations.
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